English  |  正體中文  |  简体中文  |  Items with full text/Total items : 92958/108462 (86%)
Visitors : 20363737      Online Users : 175
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/8761


    Title: What is the key point for designing HER2 inhibitors?
    Authors: Huang, Hung-Jin;Bau, Da-Tian;Tsai, Ming-Hsui;Hsu, Yuan-Man;Ho, Tin-Yun;Chen, Chien-Yu;Chang, Yea-Huey;Tsai, Fuu-Jen;Tsai, Chang-Hai;Chen, Calvin Yu-Chian
    Contributors: Department of Biotechnology
    Keywords: Docking;Drug interactions;Hydrogen bonds;ATP-binding;Cancer treatment;Clinical trails;Drug Design;Homology modeling;Hydrogen bond interaction;Keypoints;Over-expression;Pi-stacking;Protein kinase;Structure-based;Traditional Chinese Medicine
    Date: 2009
    Issue Date: 2010-04-08 19:17:49 (UTC+8)
    Publisher: Asia University
    Abstract: HER2 over-expression associates with many cancer symptoms, and the HER2 protein kinase was regarded as the target for cancer treatment. To develop the novel potent leads, homology modeling and structure-based design were employed to this research. Three clinical trail drugs and traditional Chinese medicine (TCM) database were employed to perform the docking. The top 7 compounds from database with higher DockScore were selected to develop 210 virtual compounds by De novo evolution, and the 210 derivative compounds were further conform the Lipinski's Rule (rule of five) to ensure the rational in real condition. In the docking result of serial selection, CLC015-5, CLC015-11, CLC015-12, CLC604-11, and CLC604-18 presented the pi-stacking interaction and hydrogen bond interaction with the key residues, and had higher DockScore than clinical trail drugs and original compounds. These five selected compounds were suggested the potent ATP-binding inhibitors and might guide for further drug design. ©2009 IEEE.
    Relation: Proceedings of the 2009 2nd International Conference on Biomedical Engineering and Informatics, BMEI 2009
    Appears in Collections:[生物科技學系] 會議論文

    Files in This Item:

    File Description SizeFormat
    0KbUnknown599View/Open
    310904400-8761.doc40KbMicrosoft Word523View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback